Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

ibits the rapid firing nerve cells that cause seizures, has been developed to address the need for a new anti-epileptic agent that offers a reduction in seizure frequency combined with a favourable tolerability profile. Zebinix(TM) is currently under review by the EMEA (European Medicines Agency) for the treatment of partial-onset seizures with or without secondary generalisation in combination with other anti-epileptic drugs. A US NDA (New Drug Application) is expected later in 2008 or early 2009.

About the trials

The three phase III, multi-centre, randomised, placebo controlled trials involved more than 1,000 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs.(2,3,4)

During the trials, patients were randomised to eslicarbazepine acetate or placebo and after a 2-week titration period, were assessed over a 12 week maintenance period, with continued follow-up over a one year open-label period.(2,3,4,7)

Efficacy

Over the 12 week maintenance period, Zebinix(TM) 800mg and 1200mg reduced seizure frequency by over one third, and was significantly more effective than placebo. This significant decrease in seizure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy..(2,3,4) Similar positive findings were observed in the responder rate (greater-than-or-equal-to 50% decrease in seizure frequency) for Zebinix(TM) 800mg and 1200mg that ranged between 32% and 43% across all three phase III trials. (2,3,4)

Tolerability

The safety profile of Zebinix(TM) was favourable. The majority of treatment related adverse events were mild or moderate in severity and after 6 weeks, no relevant differences in the incidence of adverse events were apparent between patients treated with eslicarbazepine acetate and patients treated with placebo. In patients treated with Zebi
'/>"/>

SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Stryker Corporation,s Orthopaedics Division, the Official Joint Replacement Products of ... of joint health to golf fans in its home state ... The Barclays.  The company,s fan destination – "The Stryker Mobility ... 17 th fairway at the Ridgewood Country Club in ... st .    At The Barclays, Stryker will ...
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
(Date:8/19/2014)... , August 19, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... that the Intellectual Property Department of ... for its invention, titled "Methods and Compositions for ... Pharmaceuticals  Oramed Pharmaceuticals is a technology ...
Breaking Medicine Technology:Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3
... Feb. 9, 2012 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... a leading China-based exporter and retailer of high-quality medical ... reported consolidated financial results for the first quarter of ... First Quarter of Fiscal 2012 Financial Highlights ...
... 9, 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... shares of its common stock pursuant to an effective shelf ... is the sole book-running manager of the offering, and Halozyme ... purchase up to an additional 1,020,000 shares of common stock. ...
Cached Medicine Technology:Winner Medical Reports First Quarter of Fiscal 2012 Results 2Winner Medical Reports First Quarter of Fiscal 2012 Results 3Winner Medical Reports First Quarter of Fiscal 2012 Results 4Winner Medical Reports First Quarter of Fiscal 2012 Results 5Winner Medical Reports First Quarter of Fiscal 2012 Results 6Winner Medical Reports First Quarter of Fiscal 2012 Results 7Winner Medical Reports First Quarter of Fiscal 2012 Results 8Winner Medical Reports First Quarter of Fiscal 2012 Results 9Winner Medical Reports First Quarter of Fiscal 2012 Results 10Winner Medical Reports First Quarter of Fiscal 2012 Results 11Winner Medical Reports First Quarter of Fiscal 2012 Results 12Winner Medical Reports First Quarter of Fiscal 2012 Results 13Winner Medical Reports First Quarter of Fiscal 2012 Results 14Winner Medical Reports First Quarter of Fiscal 2012 Results 15Winner Medical Reports First Quarter of Fiscal 2012 Results 16Winner Medical Reports First Quarter of Fiscal 2012 Results 17Winner Medical Reports First Quarter of Fiscal 2012 Results 18Halozyme Announces Proposed Public Offering of Common Stock 2Halozyme Announces Proposed Public Offering of Common Stock 3
(Date:8/20/2014)... Botanica Day Spa ... the new and popular stem cell line from ... and wrinkles and naturally repairs the skin. The ... new service by offering clients a complimentary dermaplaning ... facial. , Pevonia® continues to be a global ...
(Date:8/20/2014)... has been chosen by Plymouth University to be an ... April 2009 to raise awareness of, and funding for, ... brain tumour patients. , A range of events and ... the charity, and members of staff and students, as ... donate, fundraise and volunteer. The involvement of the wider ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 New Jersey’s ... needs of an estimated tens of thousands of patients ... new Bill A3525—a bill that would expand the list ... their own cannabis—earlier this summer by State Assemblywoman Linda ... medicinal quality marijuana is growing. , To help fill ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... Nanophase Technologies (Nasdaq: NANX ) ... products, announced today that the Company accepted the resignation ... Chief Technology Officer, so that he may pursue new ... several of the Company,s key patents and served as ...
... 3 WXYZ is proud to announce that ... Peter Nielsen , will now be seen exclusively on Channel ... than 15 years Peter Nielsen has hosted the nationally syndicated ... the author of numerous books and videos on health and fitness and ...
... the day has surprising impact on young people GAITHERSBURG, ... the importance of breakfast for students, Sodexo, a leading ... 470 school districts across the country, has created a ... time for National School Breakfast Week, March 2-6."Studies repeatedly ...
... to Improve, Automate Health Care in Master-Planned CommunitiesSCOTTSDALE, Ariz., ... of acres across the West but it,s his company,s ... would radically alter the use of energy grids. ... that message this week to The Wall Street Journal,s ...
... Exhibit www.donaldverger.com PORTLAND, Maine, March 3 A ... jail over a period of three days at ... the charges were dismissed, Verger was compelled to ... http://www.newscom.com/cgi-bin/prnh/20090303/NE78221 )"We are deeply grateful to Mr. ...
... of Pennsylvania School of Medicine and the University ... cells that spur misplaced bone growth. Unexpectedly, the ... vessels deep within skeletal muscle and other connective ... work also shows that cells important in the ...
Cached Medicine News:Health News:Nanophase Announces Changes in Principal Officers and Directors 2Health News:Nanophase Announces Changes in Principal Officers and Directors 3Health News:Peter Nielsen Has a New Home on WXYZ-TV! 2Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Innovative Plans by Major Arizona-Based Developer Sparks Landmark Energy Conservation Legislation in Multiple States to Urge Federal Action at Wall Street Journal Conference This Week with Gore, Google CEO & T. Boone Pickens 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 3Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 4Health News:Misplaced metamorphosis 2
... innovative B-Twin Expandable Spinal System is intended ... The Implant - preloaded on its Delivery ... intervertebral space in a reduced configuration of ... up to 15mm (depending on the size ...
... on the Alpha 5 include a newly ... digital processor specifically designed for ultrasonic signals. ... reduces image speckle and enables clearer imaging ... The enhanced user confidence afforded by Alpha ...
... NCP-2, ACS proudly introduces full disclosure to ... tools for assessing the administration of ECP ... ECP Treatment Report.,The ACS Treatment Report is ... both physicians and therapists to review patient ...
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
Medicine Products: